Montelukast alleviates levels of inflammatory factors and chemokines in patients with allergic rhinitis

Key Points

• Montelukast significantly reduces levels of inflammatory factors and chemokines in patients with allergic rhinitis, indicating its therapeutic potential.
• The study observed a notable decrease in markers of inflammation, improving symptoms for individuals suffering from allergic rhinitis.
• Analysis focused on the impact of montelukast, a leukotriene receptor antagonist, on immune response activity related to allergic rhinitis symptoms.
• Potential benefits highlight a new avenue for managing allergic rhinitis effectively and improving patient quality of life.